Publication:
miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrine

Thumbnail Image
Files
Wang-39-497-509-2024 (1).pdf(8.57 MB)
Date
2024
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Wang, Min ; Liu, Kai ; Zhou, Zhongming ; Geng, Huizhuan
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-657
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Background. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer. Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638. Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638. Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatment
publication.page.subject
miR-638 , NCAPG2 , Tetrandrine , Cervical cancer
Citation
Histology and Histopathology Vol. 39, nº4 (2024)
URI
http://hdl.handle.net/10201/140670
item.page.embargo
Collections
Histology and histopathology Vol.39, nº4 (2024)
Ir a Estadísticas